DISP2
gene geneOn this page
Also known as DISPBKIAA1742HsT16908
Summary
DISP2 (dispatched RND transporter family member 2, HGNC:19712) is a protein-coding gene on chromosome 15q15.1, encoding Protein dispatched homolog 2 (A7MBM2).
This gene is one of two human homologs of a segment-polarity gene known as dispatched identified in Drosophila. The product of this gene may be required for normal Hedgehog (Hh) signaling during embryonic pattern formation.
Source: NCBI Gene 85455 — RefSeq curated summary.
At a glance
- GWAS associations: 4
- Clinical variants (ClinVar): 256 total
- GTEx eGene: eQTL in 47 tissues, sQTL in 0 (q < 0.05)
- Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.81 (unconstrained)
- MANE Select transcript:
NM_033510 - Notable: 256 clinical variants but no curated precision-oncology (CIViC) evidence yet
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:19712 |
| Approved symbol | DISP2 |
| Name | dispatched RND transporter family member 2 |
| Location | 15q15.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | DISPB, KIAA1742, HsT16908 |
| Ensembl gene | ENSG00000140323 |
| Ensembl biotype | protein_coding |
| OMIM | 607503 |
| Entrez | 85455 |
Gene structure
Transcript identifiers
Ensembl transcripts: 6 — 3 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron
MANE Select: ENST00000267889
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 3: 3
ENST00000267889, ENST00000558623, ENST00000559721, ENST00000561261, ENST00000949524, ENST00000949525
RefSeq mRNA: 1 — MANE Select: NM_033510
NM_033510
CCDS: CCDS10056
Canonical transcript exons
ENST00000267889 — 8 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000942468 | 40364838 | 40364953 |
| ENSE00000942469 | 40365147 | 40365274 |
| ENSE00000942470 | 40365628 | 40365725 |
| ENSE00000942471 | 40367058 | 40378621 |
| ENSE00001099980 | 40363625 | 40363954 |
| ENSE00001099989 | 40364226 | 40364255 |
| ENSE00001099995 | 40364421 | 40364544 |
| ENSE00001100000 | 40358219 | 40358440 |
Expression profiles
Bgee: expression breadth ubiquitous, 184 present calls, max score 93.86.
FANTOM5 (CAGE): breadth broad, TPM avg 1.7863 / max 155.0087, expressed in 312 samples.
Highest expression (Bgee): cerebellar cortex, cerebellar hemisphere, hemisphere of cerebellum, cerebellum, cerebellar vermis.
Genetic regulation across tissues (GTEx eQTL / sQTL)
DISP2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 47 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
showing 20 of 47 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Skin Sun Exposed Lower leg | eqtl | 2.2e-89 | +1.28 | 15:40413218:G:A |
| Skin Not Sun Exposed Suprapubic | eqtl | 1.4e-64 | +1.20 | 15:40430582:T:G |
| Adipose Subcutaneous | eqtl | 8.3e-64 | +1.12 | 15:40413218:G:A |
| Esophagus Muscularis | eqtl | 3.7e-63 | +1.10 | 15:40413218:G:A |
| Cells Cultured fibroblasts | eqtl | 2.6e-62 | +1.03 | 15:40413218:G:A |
| Muscle Skeletal | eqtl | 2.8e-62 | +1.00 | 15:40413218:G:A |
| Adipose Visceral Omentum | eqtl | 2.4e-59 | +1.15 | 15:40413218:G:A |
| Nerve Tibial | eqtl | 1.6e-58 | +1.12 | 15:40413218:G:A |
| Esophagus Mucosa | eqtl | 3.6e-57 | +1.15 | 15:40413218:G:A |
| Breast Mammary Tissue | eqtl | 7.8e-48 | +1.13 | 15:40430582:T:G |
| Testis | eqtl | 8.6e-44 | +0.95 | 15:40413218:G:A |
| Esophagus Gastroesophageal Junction | eqtl | 1.1e-43 | +1.24 | 15:40413218:G:A |
| Lung | eqtl | 2.5e-43 | +0.93 | 15:40413218:G:A |
| Brain Nucleus accumbens basal ganglia | eqtl | 2.5e-37 | +0.57 | 15:40363243:C:T |
| Brain Caudate basal ganglia | eqtl | 2.4e-35 | +0.60 | 15:40358201:C:G |
| Artery Tibial | eqtl | 2.5e-35 | +0.75 | 15:40413218:G:A |
| Brain Putamen basal ganglia | eqtl | 2.4e-34 | +0.74 | 15:40358201:C:G |
| Heart Atrial Appendage | eqtl | 4.1e-34 | +0.98 | 15:40413218:G:A |
| Colon Sigmoid | eqtl | 6.0e-34 | +0.78 | 15:40413218:G:A |
| Pituitary | eqtl | 2.4e-33 | +0.87 | 15:40358201:C:G |
FANTOM5 promoters
2 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 146097 | 1.2911 | 204 |
| 146096 | 0.4952 | 174 |
Top tissues by expression
showing 100 of 254 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| cerebellar cortex | UBERON:0002129 | 93.86 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 93.84 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 93.68 | gold quality |
| cerebellum | UBERON:0002037 | 93.49 | gold quality |
| cerebellar vermis | UBERON:0004720 | 92.05 | gold quality |
| cortical plate | UBERON:0005343 | 91.15 | gold quality |
| right frontal lobe | UBERON:0002810 | 87.38 | gold quality |
| prefrontal cortex | UBERON:0000451 | 86.37 | gold quality |
| hypothalamus | UBERON:0001898 | 86.25 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 86.14 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 85.88 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 85.77 | gold quality |
| frontal cortex | UBERON:0001870 | 85.41 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 85.31 | gold quality |
| neocortex | UBERON:0001950 | 85.27 | gold quality |
| sural nerve | UBERON:0015488 | 85.03 | gold quality |
| ileal mucosa | UBERON:0000331 | 84.78 | gold quality |
| amygdala | UBERON:0001876 | 84.68 | gold quality |
| cerebral cortex | UBERON:0000956 | 84.43 | gold quality |
| embryo | UBERON:0000922 | 84.42 | gold quality |
| ganglionic eminence | UBERON:0004023 | 84.42 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 83.24 | gold quality |
| temporal lobe | UBERON:0001871 | 83.14 | gold quality |
| Ammon’s horn | UBERON:0001954 | 82.84 | gold quality |
| brain | UBERON:0000955 | 82.70 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 82.26 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 82.26 | gold quality |
| entorhinal cortex | UBERON:0002728 | 82.23 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 81.88 | gold quality |
| primary visual cortex | UBERON:0002436 | 81.77 | gold quality |
| forebrain | UBERON:0001890 | 81.72 | gold quality |
| nucleus accumbens | UBERON:0001882 | 80.08 | gold quality |
| postcentral gyrus | UBERON:0002581 | 79.95 | gold quality |
| thyroid gland | UBERON:0002046 | 79.81 | gold quality |
| caudate nucleus | UBERON:0001873 | 79.02 | gold quality |
| parietal lobe | UBERON:0001872 | 78.75 | gold quality |
| occipital lobe | UBERON:0002021 | 78.33 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 78.32 | gold quality |
| putamen | UBERON:0001874 | 77.82 | gold quality |
| substantia nigra | UBERON:0002038 | 77.59 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 77.24 | gold quality |
| adenohypophysis | UBERON:0002196 | 76.98 | gold quality |
| islet of Langerhans | UBERON:0000006 | 76.52 | gold quality |
| midbrain | UBERON:0001891 | 76.26 | gold quality |
| pituitary gland | UBERON:0000007 | 75.53 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 74.49 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 74.46 | gold quality |
| ventricular zone | UBERON:0003053 | 73.64 | gold quality |
| spinal cord | UBERON:0002240 | 73.54 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 73.46 | gold quality |
| rectum | UBERON:0001052 | 73.36 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 72.33 | gold quality |
| transverse colon | UBERON:0001157 | 72.09 | gold quality |
| endothelial cell | CL:0000115 | 71.78 | silver quality |
| colonic mucosa | UBERON:0000317 | 71.78 | gold quality |
| pancreatic ductal cell | CL:0002079 | 69.44 | silver quality |
| apex of heart | UBERON:0002098 | 69.23 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 69.19 | gold quality |
| ventral tegmental area | UBERON:0002691 | 68.83 | gold quality |
| substantia nigra pars compacta | UBERON:0001965 | 68.33 | gold quality |
| secondary oocyte | CL:0000655 | 68.20 | silver quality |
| small intestine | UBERON:0002108 | 68.00 | gold quality |
| dorsal root ganglion | UBERON:0000044 | 67.98 | gold quality |
| colon | UBERON:0001155 | 67.59 | gold quality |
| large intestine | UBERON:0000059 | 67.49 | gold quality |
| intestine | UBERON:0000160 | 67.35 | gold quality |
| duodenum | UBERON:0002114 | 67.27 | gold quality |
| trigeminal ganglion | UBERON:0001675 | 66.87 | gold quality |
| oocyte | CL:0000023 | 66.28 | gold quality |
| adult organism | UBERON:0007023 | 66.09 | gold quality |
| pancreas | UBERON:0001264 | 65.53 | gold quality |
| pons | UBERON:0000988 | 65.23 | gold quality |
| lymph node | UBERON:0000029 | 64.94 | gold quality |
| superior vestibular nucleus | UBERON:0007227 | 64.75 | gold quality |
| bone marrow cell | CL:0002092 | 64.63 | silver quality |
| medulla oblongata | UBERON:0001896 | 64.60 | gold quality |
| body of stomach | UBERON:0001161 | 64.42 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 64.11 | silver quality |
| granulocyte | CL:0000094 | 63.38 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 62.79 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 62.71 | silver quality |
| corpus callosum | UBERON:0002336 | 62.56 | gold quality |
| vermiform appendix | UBERON:0001154 | 62.24 | gold quality |
| stomach | UBERON:0000945 | 62.19 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 62.18 | gold quality |
| mucosa of stomach | UBERON:0001199 | 62.06 | gold quality |
| dorsal plus ventral thalamus | UBERON:0001897 | 62.05 | silver quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 61.80 | gold quality |
| right testis | UBERON:0004534 | 61.72 | gold quality |
| left testis | UBERON:0004533 | 61.60 | gold quality |
| testis | UBERON:0000473 | 61.57 | gold quality |
| body of pancreas | UBERON:0001150 | 61.06 | gold quality |
| caecum | UBERON:0001153 | 60.63 | gold quality |
| tibialis anterior | UBERON:0001385 | 59.99 | silver quality |
| colonic epithelium | UBERON:0000397 | 59.53 | gold quality |
| anatomical system | UBERON:0000467 | 59.53 | gold quality |
| subthalamic nucleus | UBERON:0001906 | 59.21 | silver quality |
| multicellular organism | UBERON:0000468 | 59.20 | gold quality |
| material anatomical entity | UBERON:0000465 | 59.19 | gold quality |
| thymus | UBERON:0002370 | 59.09 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-5061 | yes | 13.30 |
| E-ANND-3 | yes | 6.24 |
| E-GEOD-109979 | no | 59.31 |
HPA expression
RNA tissue specificity: Tissue enriched
showing 60 of 70 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM |
|---|---|---|
| Frontal cortex | tissue | 79.4 |
| Caudate putamen | tissue | 49.4 |
| Cerebellum | tissue | 40.8 |
| Postcentral gyrus | tissue | 24.4 |
| Hippocampal formation | tissue | 21.6 |
| Prefrontal cortex | tissue | 19.9 |
| Cerebral cortex | tissue | 19.9 |
| Locus coeruleus | tissue | 18.5 |
| Motor cortex | tissue | 17.8 |
| Retrosplenial and cingulate cortex | tissue | 17.7 |
| Insular cortex | tissue | 17.7 |
| Entorhinal cortex | tissue | 17.4 |
| Hippocampus | tissue | 16.9 |
| Somatosensory cortex | tissue | 16.9 |
| Retrosplenial cortex | tissue | 16.9 |
| Occipital cortex | tissue | 15.2 |
| Temporal cortex | tissue | 14.0 |
| Amygdala | tissue | 13.5 |
| Nucleus accumbens | tissue | 12.1 |
| Hypothalamus | tissue | 10.5 |
| Basal ganglia | tissue | 9.8 |
| Pons | tissue | 8.9 |
| Septum | tissue | 8.5 |
| Olfactory bulb | tissue | 8.4 |
| Ventral forebrain | tissue | 8.2 |
| Putamen | tissue | 7.9 |
| Thalamus | tissue | 7.8 |
| Midbrain | tissue | 7.1 |
| Substantia nigra | tissue | 6.8 |
| Periaqueductal gray | tissue | 6.1 |
| Superior colliculi | tissue | 5.0 |
| Medulla oblongata | tissue | 4.2 |
| Spinal cord | tissue | 2.9 |
| Choroid plexus | tissue | 2.6 |
| Corpus callosum | tissue | 2.5 |
| Retina | tissue | 1.4 |
| Pituitary gland | tissue | 1.2 |
| Colon | tissue | 1.2 |
| Stomach 1 | tissue | 1.1 |
| Rectum | tissue | 1.1 |
| Thyroid gland | tissue | 1.0 |
| Duodenum | tissue | 1.0 |
| Small intestine | tissue | 0.8 |
| Testis | tissue | 0.6 |
| Adrenal gland | tissue | 0.6 |
| Seminal vesicle | tissue | 0.4 |
| Lymph node | tissue | 0.3 |
| Smooth muscle | tissue | 0.3 |
| Pancreas | tissue | 0.3 |
| Appendix | tissue | 0.3 |
| Skin 1 | tissue | 0.2 |
| Salivary gland | tissue | 0.2 |
| Placenta | tissue | 0.2 |
| Spleen | tissue | 0.2 |
| Gallbladder | tissue | 0.2 |
| Bone marrow | tissue | 0.2 |
| Fallopian tube | tissue | 0.2 |
| Cervix | tissue | 0.1 |
| Heart muscle | tissue | 0.1 |
| Ovary | tissue | 0.1 |
Brain sub-regions (HPA Brain Atlas): detected in 188; highest nTPM — Cerebellar cortex (49.5), Vermis (48.8), Flocculonodular lobe (48.5), Ventral periolivary nuclei (24.9), Nuclei of the trapezoid body (24.6).
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
Targeting DISP2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 50 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6758-5P | 100.00 | 66.21 | 1470 |
| HSA-MIR-6856-5P | 100.00 | 65.47 | 1298 |
| HSA-MIR-518D-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-518E-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-518F-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-519A-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-519B-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-519C-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-520C-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-522-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-523-5P | 100.00 | 67.66 | 954 |
| HSA-MIR-526A-5P | 100.00 | 67.51 | 979 |
| HSA-MIR-4531 | 99.99 | 69.70 | 3181 |
| HSA-MIR-520G-5P | 99.99 | 66.76 | 658 |
| HSA-MIR-3150A-3P | 99.76 | 64.44 | 1640 |
| HSA-MIR-6763-5P | 99.76 | 64.68 | 1767 |
| HSA-MIR-6887-3P | 99.66 | 67.83 | 1778 |
| HSA-MIR-452-5P | 99.65 | 69.63 | 1762 |
| HSA-MIR-4676-3P | 99.65 | 69.31 | 1733 |
| HSA-MIR-892C-3P | 99.65 | 69.38 | 1745 |
| HSA-MIR-3175 | 99.65 | 66.30 | 2031 |
| HSA-MIR-6132 | 99.60 | 65.83 | 1554 |
| HSA-MIR-516B-5P | 99.56 | 66.33 | 1495 |
| HSA-MIR-1207-5P | 99.49 | 69.11 | 2983 |
| HSA-MIR-12131 | 99.48 | 68.72 | 1673 |
| HSA-MIR-6081 | 99.48 | 66.07 | 1446 |
| HSA-MIR-12132 | 99.47 | 68.90 | 1341 |
| HSA-MIR-4641 | 99.28 | 66.64 | 744 |
| HSA-MIR-4505 | 99.27 | 67.81 | 2678 |
| HSA-MIR-3922-3P | 99.25 | 64.96 | 1136 |
Functional genomics
gnomAD constraint: pLI 1.1e-12, LOEUF 0.813, missense Z 0.285 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD)
ENST00000267889 splits into 5 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD
| Region (GRCh38) | Missense obs / exp | o/e | Constrained |
|---|---|---|---|
| 15:40,358,322–40,365,263 | 342 / 364.3 | 0.94 | no |
| 15:40,365,264–40,365,703 | 14 / 36.6 | 0.38 | no |
| 15:40,365,704–40,368,593 | 732 / 714.6 | 1.02 | no |
| 15:40,368,594–40,369,512 | 317 / 394.9 | 0.80 | no |
| 15:40,369,513–40,370,315 | 347 / 344.2 | 1.01 | no |
Literature-anchored findings (GeneRIF, showing 1)
- A Hypermutable Region in the DISP2 Gene Links to Natural Selection and Late-Onset Neurocognitive Disorders in Humans. (PMID:38565786)
Cross-species orthologs
9 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | disp2 | ENSDARG00000042846 |
| mus_musculus | Disp2 | ENSMUSG00000040035 |
| rattus_norvegicus | Disp2 | ENSRNOG00000026787 |
| drosophila_melanogaster | ptc | FBGN0003892 |
| drosophila_melanogaster | disp | FBGN0029088 |
| drosophila_melanogaster | Ptr | FBGN0262867 |
| caenorhabditis_elegans | WBGENE00004208 | |
| caenorhabditis_elegans | WBGENE00004211 | |
| caenorhabditis_elegans | ptr-17 | WBGENE00004231 |
Paralogs (10): NPC1L1 (ENSG00000015520), SCAP (ENSG00000114650), PTCH2 (ENSG00000117425), NPC1 (ENSG00000141458), DISP1 (ENSG00000154309), PTCHD1 (ENSG00000165186), PTCHD3 (ENSG00000182077), PTCH1 (ENSG00000185920), DISP3 (ENSG00000204624), PTCHD4 (ENSG00000244694)
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| INAFM2 | protein-coding | 100505573 |
| CCDC9B | protein-coding | 388115 |
| PHGR1 | protein-coding | 644844 |
| IVD | protein-coding | 3712 |
| KNSTRN | protein-coding | 90417 |
| BAHD1 | protein-coding | 22893 |
| CHST14 | protein-coding | 113189 |
Protein
Protein identifiers
Protein dispatched homolog 2 — A7MBM2 (reviewed: A7MBM2)
All UniProt accessions (1): A7MBM2
UniProt curated annotations — full annotation on UniProt →
Subcellular location. Membrane.
Similarity. Belongs to the dispatched family.
RefSeq proteins (1): NP_277045* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000731 | SSD | Domain |
| IPR052081 | Dispatched | Family |
UniProt features (37 total): transmembrane region 12, region of interest 6, sequence variant 5, compositionally biased region 4, sequence conflict 4, glycosylation site 3, chain 1, domain 1, modified residue 1
Structure
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-A7MBM2-F1 | 68.24 | 0.27 |
Human Protein Atlas
Protein class: Predicted membrane proteins, UniProt - Evidence at transcript level
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): nucleoplasm; vesicles
Antibody reliability (HPA): IH uncertain · IF approved
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1)
| Type | Positions |
|---|---|
| Omega-n-methylarginine | 1366 |
Glycosylation sites (3)
| Type | Positions |
|---|---|
| N-linked (glcnac…) asparagine | 239, 349, 465 |
Function
Pathways and Gene Ontology
Reactome pathways
0 curated (TAS) of 4; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
4 pathways:
| ID | Pathway | Evidence |
|---|---|---|
| R-HSA-5358346 | Hedgehog ligand biogenesis | — |
| R-HSA-5362798 | Release of Hh-Np from the secreting cell | electronic |
| R-HSA-162582 | Signal Transduction | — |
| R-HSA-5358351 | Signaling by Hedgehog | — |
MSigDB gene sets: 52 (showing top):
GOBP_SMOOTHENED_SIGNALING_PATHWAY, GCCATNTTG_YY1_Q6, LEIN_NEURON_MARKERS, GSE13762_CTRL_VS_125_VITAMIND_DAY5_DC_DN, GSE13522_WT_VS_IFNG_KO_SKIN_DN, WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_DN, WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_36HR, WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_8D, SRC_UP.V1_DN, REACTOME_HEDGEHOG_LIGAND_BIOGENESIS, REACTOME_SIGNALING_BY_HEDGEHOG, REACTOME_RELEASE_OF_HH_NP_FROM_THE_SECRETING_CELL, NRF1_Q6, GSE14415_ACT_TCONV_VS_ACT_NATURAL_TREG_UP, GSE14415_FOXP3_KO_NATURAL_TREG_VS_TCONV_UP
GO Biological Process (1): smoothened signaling pathway (GO:0007224)
GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)
Reactome top-level categories
3 top-level categories:
| Category | Pathways |
|---|---|
| Hedgehog ligand biogenesis | 1 |
| Signaling by Hedgehog | 1 |
| Signal Transduction | 1 |
GO top-level categories
4 GO namespaces:
| Category | Terms |
|---|---|
| cell surface receptor signaling pathway | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
showing 15 of 398 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| DISP2 | SHH | Q15465 | 632 |
| DISP2 | PTCH1 | Q13635 | 556 |
| DISP2 | DISP3 | Q9P2K9 | 514 |
| DISP2 | MAP6D1 | Q9H9H5 | 476 |
| DISP2 | COMTD1 | Q86VU5 | 468 |
| DISP2 | LIX1L | Q8IVB5 | 465 |
| DISP2 | PAXBP1 | Q9Y5B6 | 464 |
| DISP2 | DUS2 | Q9NX74 | 458 |
| DISP2 | COPRS | Q9NQ92 | 447 |
| DISP2 | RASSF2 | P50749 | 446 |
| DISP2 | TMC4 | Q7Z404 | 446 |
| DISP2 | FAM185A | Q8N0U4 | 436 |
| DISP2 | PGCKA1 | Q8IY42 | 406 |
| DISP2 | PTCH2 | Q9Y6C5 | 399 |
| DISP2 | SUFU | Q9UMX1 | 394 |
IntAct
Human interaction partners of DISP2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
1 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| CACNA1C | association | 0.350 | 1 |
BioGRID (3 interactions; top human partners by supporting records): DDX39A (Affinity Capture-RNA), KIAA1429 (Affinity Capture-RNA), TOP3B (Affinity Capture-RNA)
Disease & clinical
Genetic variants
Variant evidence for DISP2: 256 ClinVar records (0 pathogenic / likely pathogenic); 4 GWAS associations.
ClinVar
256 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 236 |
| Likely benign | 9 |
| Benign | 1 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 44 predictions of 668):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 15:40364419–40364420 | acceptor_loss | 1.0000 | 6 |
| 15:40364545–40364546 | donor_loss | 1.0000 | 5 |
| 15:40358387 | donor_gain | 0.9900 | |
| 15:40358441–40358442 | donor_loss | 0.9900 | 5 |
| 15:40363955–40363956 | donor_loss | 0.9900 | 5 |
| 15:40358442 | donor_loss | 0.9800 | |
| 15:40363623–40363624 | acceptor_loss | 0.9800 | 6 |
| 15:40364224–40364225 | acceptor_loss | 0.9800 | 6 |
| 15:40364836–40364837 | acceptor_loss | 0.9800 | 5 |
| 15:40365145–40365146 | acceptor_loss | 0.9800 | 4 |
AlphaMissense
2,072 missense substitutions predicted likely pathogenic (of 9,002 scored), across 612 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| F420 | 8 | 0.959 | 0.995 |
| D417 | 8 | 0.953 | 0.989 |
| F757 | 8 | 0.950 | 0.994 |
| F702 | 8 | 0.936 | 0.990 |
| F740 | 8 | 0.924 | 0.975 |
| D488 | 8 | 0.919 | 0.972 |
| F691 | 8 | 0.907 | 0.959 |
| F291 | 8 | 0.902 | 0.993 |
| F759 | 8 | 0.902 | 0.981 |
| F710 | 8 | 0.900 | 0.973 |
| F801 | 8 | 0.900 | 0.977 |
| F746 | 8 | 0.879 | 0.965 |
| F907 | 8 | 0.874 | 0.979 |
| F1107 | 8 | 0.868 | 0.958 |
| F203 | 8 | 0.847 | 0.957 |
| F439 | 8 | 0.837 | 0.979 |
| S1183 | 8 | 0.830 | 0.986 |
| F540 | 8 | 0.829 | 0.935 |
| D360 | 8 | 0.827 | 0.951 |
| D1031 | 8 | 0.820 | 0.911 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
2 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Pancreatic Adenocarcinoma (validation) | unfavorable | 0.000163 |
| Glioblastoma Multiforme (validation) | favorable | 0.000715 |
Disease associations
OMIM: gene MIM:607503 | disease phenotypes:
GWAS associations
4 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST006479_26 | Diverticular disease | 9e-11 |
| GCST010725_98 | Malaria | 2e-6 |
| GCST010725_13 | Malaria | 3e-6 |
| GCST010725_30 | Malaria | 7e-6 |
EFO canonical traits (from GWAS)
1 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0009959 | diverticular disease |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
26 total (human), top 26 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | increases expression, increases methylation | 2 |
| Cadmium Chloride | decreases expression, increases expression | 2 |
| FR900359 | increases phosphorylation | 1 |
| aminomethylphosphonic acid (AMPA) | decreases expression | 1 |
| bisphenol A | increases expression | 1 |
| beta-lapachone | decreases expression | 1 |
| sodium arsenite | affects expression | 1 |
| S-(1,2-dichlorovinyl)cysteine | affects response to substance, increases expression, affects cotreatment, decreases expression | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| abrine | decreases expression | 1 |
| (+)-JQ1 compound | increases expression | 1 |
| 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid | decreases expression | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Air Pollutants | decreases expression, increases abundance | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Estradiol | affects cotreatment, increases expression | 1 |
| Lipopolysaccharides | decreases expression, affects response to substance, increases expression, affects cotreatment | 1 |
| Plant Extracts | affects cotreatment, decreases expression | 1 |
| Silicon Dioxide | increases expression | 1 |
| Smoke | decreases expression | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
| Triclosan | increases expression | 1 |
| Tunicamycin | decreases expression | 1 |
| 2,4-Dichlorophenoxyacetic Acid | decreases expression | 1 |
| Copper Sulfate | increases expression | 1 |
| Particulate Matter | decreases expression, increases abundance | 1 |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.